Moscow, Moscow, Russia The main office of represented Corporate Investor is situated in the Moscow. The fund was located in Europe if to be more exact in Russian Federation.
The standard case for the fund is to invest in rounds with 4-5 partakers. Despite the Pharmstandard, startups are often financed by Torrey Pines Investment, Intersouth Partners, TVM Capital. The meaningful sponsors for the fund in investment in the same round are Inbio Ventures, Virginia Tech Carilion (VTC) Innovation Fund, Intersouth Partners. In the next rounds fund is usually obtained by Inbio Ventures, yet2Ventures, Wellington Management.
Comparing to the other companies, this Pharmstandard performs on 26 percentage points more the average number of lead investments. The real fund results show that this Corporate Investor is 35 percentage points more often commits exit comparing to other companies. Deals in the range of 10 - 50 millions dollars are the general things for fund. The high activity for fund was in 2016. Despite it in 2019 the fund had an activity. The fund is generally included in less than 2 deals every year. The top amount of exits for fund were in 2017.
Besides, a startup needs to be aged 6-10 years to get the investment from the fund. Among the most popular fund investment industries, there are Real Time, Medical. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. The fund has no specific favorite in a number of founders of portfolio startups. In case when startup counts 4 of the founder, the chance for it to get the investment is meager. Among the most popular portfolio startups of the fund, we may highlight enGene, Viriom, Avelas Biosciences.
Related Funds
| Fund Name | Location |
| Amity Supply | New York, New York, United States |
| Angels with Attitude | Seattle, United States, Washington |
| Black Dog Venture Partners | Arizona, Tempe, United States |
| Ginkgo Bioworks | Boston, Massachusetts, United States |
| Growceanu Angel Investment | - |
| Hinokiya Group | Chiyoda, Japan |
| ICONIZ | California, Los Angeles, United States |
| KD Partners | - |
| Kerlink | Bretagne, France, Rennes |
| N+1 Capital | Delhi, Delhi, India |
| Nanchang Xinshiji Chuangtou | China, Guangdong, Jiangxi |
| Neogen.biz | - |
| Next Blockchain Capital | - |
| Oakhouse Partners | California, San Francisco, United States |
| Tianjin Yahui Mingze Asset Management | China, Guangdong, Tianjin |
| Tide Capital | - |
| University of New Brunswick | Canada, Fredericton, New Brunswick |
| YMCI Group | China, Kunming, Yunnan |
| Zhongping Capital | China, Shanghai |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
| $6M | 21 Mar 2019 | Virginia, United States | |||
| $8M | 07 Dec 2017 | Virginia, United States | |||
| $12M | 06 Dec 2017 | San Diego, California, United States | |||
Genotek | $1M | 17 Feb 2017 | Moscow, Moscow, Russia | ||
Avelas Biosciences | $20M | 18 Aug 2016 | San Diego, California, United States | ||
TransMedics | $12M | 12 Jul 2016 | Massachusetts, United States | ||
| $60M | 15 Mar 2016 | Durham, North Carolina, United States | |||
Jounce Therapeutics | $56M | 23 Apr 2015 | Cambridge, Massachusetts, United States | ||
enGene | $11M | 26 Jan 2015 | Vancouver, British Columbia, Canada |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
| $6M | 21 Mar 2019 | Virginia, United States | |||
| $8M | 07 Dec 2017 | Virginia, United States | |||
| $12M | 06 Dec 2017 | San Diego, California, United States | |||
Genotek | $1M | 17 Feb 2017 | Moscow, Moscow, Russia | ||
Avelas Biosciences | $20M | 18 Aug 2016 | San Diego, California, United States | ||
TransMedics | $12M | 12 Jul 2016 | Massachusetts, United States | ||
| $60M | 15 Mar 2016 | Durham, North Carolina, United States | |||
Jounce Therapeutics | $56M | 23 Apr 2015 | Cambridge, Massachusetts, United States | ||
enGene | $11M | 26 Jan 2015 | Vancouver, British Columbia, Canada |
Get matched with relevant funds
